NCT07100067Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 30 Jul 2025
- Start date
- Sept 2025
- Primary completion date
- Feb 2028
- Lead sponsor
- Nanjing Legend Biotech Co.
- Diseases
- Multiple myeloma
- NCT number
- NCT07100067
What you commit to
- Study type: Interventional
- Planned participants: 35
- From Sept 2025 to the primary completion date, Feb 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received previous therapy targeting FcRH5 targets.
- Prior antineoplastic therapy and meet exclusion criteria (before apheresis);
- Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.
Other illness
- Subjects had Plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
- Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;
- Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.
- Serious underlying diseases were present.
Other
- Also enrolled in other clinical studies.
Who the study is looking for
- Subjects voluntarily participate in clinical research.
- Age ≥18 years old.
- Eastern Cooperative Oncology Group (ECOG) score 0-2.
- Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.
- Measurable lesions were present.
- Subjects have received treatment with one PI, one IMiD and a CD38 monoclonal antibody.
- Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria).
- Expected survival ≥3 months.
- Clinical laboratory values in the screening period meet criteria.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Boren Hospital Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Institute of Hematology & Blood Diseases Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
| Wuhan Union Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.